These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1891900)

  • 41. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effect of lipanthyl on parameters of lipid metabolism in patients with primary hyperlipoproteinemia].
    Sznajd J; Magdoń M; Idzior B; Konarska R; Malczewska M; Czarnecka H
    Przegl Lek; 1984; 41(2):217-21. PubMed ID: 6377392
    [No Abstract]   [Full Text] [Related]  

  • 43. In vivo platelet activity and lipoprotein patterns in coronary artery disease.
    Goubran F; Maklady F; Saad M; el-Ashry M
    Wien Klin Wochenschr; 1986 Apr; 98(7):209-11. PubMed ID: 3705598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
    Superko HR; Berneis KK; Williams PT; Rizzo M; Wood PD
    Am J Cardiol; 2005 Nov; 96(9):1266-72. PubMed ID: 16253595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plafibride treatment and serum lipids in hyperlipoproteinemias.
    Rodriguez F; López IM; Jover E
    J Med; 1987; 18(3-4):153-63. PubMed ID: 3323393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activity profile of gemfibrozil on the major plasma lipoprotein parameters.
    Sirtori CR; Franceschini G; Gianfranceschi G; Vaccarino V; Chiesa G; Maderna P; Bertoli M; Calabresi L
    Eur J Epidemiol; 1992 May; 8 Suppl 1():120-4. PubMed ID: 1505648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cholesterol and triglyceride plasma levels in patients with primary hyperlipoproteinemia. Decline after short-term i.v. glucagon administration].
    Andĕl M; Brodan V; Kucerová L; Grafnetter D; Kuhn E; Veselková A
    Cas Lek Cesk; 1980 May; 119(22):616-21. PubMed ID: 7427980
    [No Abstract]   [Full Text] [Related]  

  • 48. [Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia].
    Branchi A; Sommariva D; Tirrito M; Bonfiglioli D; Pini C; Scandiani L; Orlandi S; Fasoli A
    Clin Ter; 1987 Jul; 122(1):17-23. PubMed ID: 2973892
    [No Abstract]   [Full Text] [Related]  

  • 49. [Clinical study of fenofibrate in hyperlipoproteinemias].
    Ducobu J
    Acta Clin Belg; 1980; 35(3):148-54. PubMed ID: 7456965
    [No Abstract]   [Full Text] [Related]  

  • 50. Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia.
    Packard CJ; Stewart JM; Third JL; Morgan HG; Lawrie TD; Shepherd J
    Biochim Biophys Acta; 1980 Apr; 618(1):53-62. PubMed ID: 6990991
    [No Abstract]   [Full Text] [Related]  

  • 51. [Effect of bezamidine on plasma cholesterol and triglyceride levels in patients with familial hyperlipoproteinemia].
    Kukharchuk VV; Koshechkin VA; Konovalov GA; Rozhkova TA; Solov'eva EIu
    Kardiologiia; 1990 Dec; 30(12):16-8. PubMed ID: 2097388
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolism of plasma and biliary lipids in hyperlipoproteinaemia.
    Leijd B
    Acta Med Scand Suppl; 1979; 635():1-32. PubMed ID: 295570
    [No Abstract]   [Full Text] [Related]  

  • 53. CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia.
    Corder CN; Kloer HU; Price MD
    Eur J Clin Pharmacol; 1989; 37(5):477-81. PubMed ID: 2598985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pre- and post-treatment values of HDL cholesterol and total: HDL cholesterol ratio in hyperlipoproteinaemic subjects.
    Sale JK; Johnstone JH
    Ann Clin Biochem; 1981 Mar; 18 (Pt 2)():71-5. PubMed ID: 7259072
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Very low density lipoprotein (VLDL) pattern in primary hyperlipoproteinaemia type IIb and type IV.
    Kłosiewicz-Latoszek L; Naruszewicz M; Cybulska B; Szostak WB; Chotkowska E
    Mater Med Pol; 1979; 11(3):230-4. PubMed ID: 232894
    [No Abstract]   [Full Text] [Related]  

  • 56. [Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
    Sznajderman M
    Pol Arch Med Wewn; 1980 Jun; 63(6):543-9. PubMed ID: 7402954
    [No Abstract]   [Full Text] [Related]  

  • 57. [Dietary treatment of patients with familial hyperlipoproteinemias].
    Solovév EIu; Rozhkova TA; Koshechkin VA; Pogozhaeva AV
    Kardiologiia; 1992; 32(11-12):56-8. PubMed ID: 1297883
    [No Abstract]   [Full Text] [Related]  

  • 58. [Effect of phenofibrate on serum cholesterol and triglyceride concentration in patients with primary hyperlipoproteinemia].
    Cieślicka T; Paradowski S
    Pol Arch Med Wewn; 1983; 70(5-6):223-9. PubMed ID: 6677885
    [No Abstract]   [Full Text] [Related]  

  • 59. A comparison of different formulations and dosage administrations of gemfibrozil.
    Kovanen PT; Koskinen P; Manninen V
    Am J Cardiol; 1986 May; 57(14):31G-34G. PubMed ID: 3459351
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Therapy of hyperlipoproteinemia type IIa and IIb with etiroxate-HCl. Dose-response comparison].
    Banz H; Gall FP
    Fortschr Med; 1979 Nov; 97(42):1942-1947. PubMed ID: 520990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.